TherapeuticsMD, Inc.
$2.19
0%
2026-04-21 09:58:00
www.therapeuticsmd.com
NMS: TXMD
Explore TherapeuticsMD, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$25.35 M
Current Price
$2.19
52W High / Low
$2.95 / $0.95
Stock P/E
83.93
Book Value
$2.32
Dividend Yield
—
ROCE
-12.82%
ROE
-2.41%
Face Value
—
EPS
$-0.06
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1
Beta
0.56
Debt / Equity
22.69
Current Ratio
3.02
Quick Ratio
3.02
Forward P/E
5.91
Price / Sales
7.93
Enterprise Value
$22.57 M
EV / EBITDA
-11.38
EV / Revenue
7.47
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BGM Group Ltd. | $0.36 | — | $59.42 M | — | -0.81% | -3.37% | $17.17 / $0.27 | $1.85 |
| 2. | cbdMD, Inc. | $0.81 | — | $7.12 M | 0% | -29.93% | -43.36% | $2.56 / $0.47 | $0.89 |
| 3. | Lifecore Biomedical, Inc. | $5.35 | — | $200.6 M | — | -5.74% | -612.08% | $8.98 / $3.62 | $-0.38 |
| 4. | Zhengye Biotechnology Holding Limited | $0.95 | — | $47.54 M | 0.05% | 4.81% | -6.38% | $14.3 / $0.68 | $0.91 |
| 5. | Shuttle Pharmaceuticals Holdings, Inc. | $0.99 | — | $5.7 M | — | -791.36% | -7.91% | $11.25 / $0.5 | $1.13 |
| 6. | Amylyx Pharmaceuticals, Inc. | $17.57 | — | $2.03 B | — | -49.46% | -61.59% | $18.61 / $3.79 | $2.78 |
| 7. | Perrigo Company plc | $12.04 | — | $1.66 B | 9.63% | 4.16% | -38.66% | $28.43 / $9.22 | $21.33 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.89 M | 0.78 M | 0.95 M | 0.39 M | 0.67 M | — |
| Operating Profit | -1.5 M | -0.83 M | -0.69 M | -0.78 M | -0.31 M | — |
| Net Profit | -0.62 M | 0.15 M | 0.55 M | -0.65 M | 0.25 M | — |
| EPS in Rs | -0.05 | 0.01 | 0.05 | -0.06 | 0.02 | -0.05 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.02 M | 1.76 M | 1.3 M | 69.96 M |
| Operating Profit | -4.21 M | -4.84 M | -8.52 M | 10.66 M |
| Net Profit | -0.57 M | -2.18 M | -10.28 M | 112 M |
| EPS in Rs | -0.05 | -0.19 | -0.89 | 9.68 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 37.66 M | 38.82 M | 43.31 M | 90.46 M |
| Total Liabilities | 10.78 M | 11.45 M | 14.02 M | 55.31 M |
| Equity | 26.88 M | 27.37 M | 29.29 M | 35.14 M |
| Current Assets | 14.45 M | 12.26 M | 11.8 M | 55.35 M |
| Current Liabilities | 4.79 M | 5.17 M | 6.85 M | 46.84 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 2.45 M | 1.17 M | -23.08 M | 9.36 M |
| Investing CF | — | — | 0 M | -0.35 M |
| Financing CF | — | 0 M | 3.15 M | -235.21 M |
| Free CF | 2.45 M | 1.17 M | -23.08 M | 9 M |
| Capex | — | — | — | -0.35 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 35.25% | -98.14% | — | — |
| Earnings Growth % | 78.78% | -109.18% | — | — |
| Profit Margin % | -123.85% | -789.4% | 160.08% | — |
| Operating Margin % | -275.07% | -654.61% | 15.24% | — |
| Gross Margin % | — | 100% | 98% | — |
| EBITDA Margin % | -202.39% | -583.79% | 16.96% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-05-09 | 1:0.02 |